Gertjan Kaspers became pediatric oncologist/hematologist in 2000, after a fellowship from the Dutch Cancer Society. Since 2000, he has been a staff member at the Department of Pediatrics at the VU University Medical Center in Amsterdam, The Netherlands. He has chaired the Division of Pediatric Oncology/Hematology since 2002 and has been a Full Professor of this division since 2006. He is a Member of the Supervisory Board of the Dutch Childhood Oncology Group (DCOG), and chairs the disease committee Myeloid Malignancies and the protocol committees Relapsed Acute Myeloid Leukemia and Acute Promyelocytic Leukemia of the DCOG. His main clinical and translational research is on leukemia and brain stem tumors. He (co-) chairs several clinical studies on innovative treatment of childhood leukaemia, with a focus on acute myeloid leukemia and acute lymphoblastic leukemia. Kaspers is also a Member of several national and international organizations, including the International Society of Pediatric Oncology, European Haematology Association, American Association for Cancer Research, and American Society of Hematology. He is a Member of the Scientific Committee of the American Society of Hematology on Lymphoid Neoplasia. In addition, he is the Chairman of the Relapsed AML Working Group of the International BFM Study Group. He (co-) edited a series of books on drug resistance in leukemia and lymphoma, and he is the First Editor of a recent book titled Innovative Leukemia and Lymphoma Therapy.
Biography Updated on 31 May 2009